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Background. Complications from typhoid fever disease have been estimated to occur in 10%–15% of hospitalized patients, with 
evidence of a higher risk in children and when delaying the implementation of effective antimicrobial treatment. We estimated the 
prevalence of complications in hospitalized patients with culture-confirmed typhoid fever and the effects of delaying the implemen-
tation of effective antimicrobial treatment and age on the prevalence and risk of complications.
Methods. A systematic review and meta-analysis were performed using studies in the PubMed database. We rated risk of bias 
and conducted random-effects meta-analyses. Days of disease at hospitalization (DDA) was used as a surrogate for delaying the 
implementation of effective antimicrobial treatment. Analyses were stratified by DDA (DDA <10 versus ≥10 mean/median days of 
disease) and by age (children versus adults). Differences in risk were assessed using odds ratios (ORs) and 95% confidence intervals 
(CIs). Heterogeneity and publication bias were evaluated with the I2 value and funnel plot analysis, respectively.
Results. The pooled prevalence of complications estimated among hospitalized typhoid fever patients was 27% (95% CI, 21%–
32%; I2 = 90.9%, P < .0001). Patients with a DDA ≥ 10 days presented higher prevalence (36% [95% CI, 29%–43%]) and three times 
greater risk of severe disease (OR, 3.00 [95% CI, 2.14–4.17]; P < .0001) than patients arriving earlier (16% [95% CI, 13%– 18%]). 
Difference in prevalence and risk by age groups were not significant.
Conclusions. This meta-analysis identified a higher overall prevalence of complications than previously reported and a strong 
association between duration of symptoms prior to hospitalization and risk of serious complications.
Keywords. typhoid fever; complications; risk factors; meta-analysis; prevalence.
Typhoid fever is a disease caused by the bacterium Salmonella 
enterica serovar Typhi (Salmonella Typhi), which is transmitted 
through ingestion of food and water contaminated with 
feces from patients with typhoid fever or carriers [1]. Global 
estimates indicate that 11–20 million individuals are infected 
with the disease, with 120 000–220 000 dying annually [2]. The 
disease incidence is especially high in preschool children and 
infants [2–5]. Countries in South Asia have the highest inci-
dence of the disease, though recent estimates suggest a com-
paratively substantial burden in African countries [2, 6, 7].
The progression of the illness without appropriate diagnosis 
and treatment may result in the development of complications, 
usually by the second to fourth week of illness [8]. Among patients 
hospitalized with typhoid fever, complications are estimated to 
occur in 10%–15% [1], with greater risk for complications among 
typhoid fever patients with one or more of the following risk 
factors: a delay in implementing an effective antimicrobial treat-
ment [9], infection with an antimicrobial-resistant Salmonella 
Typhi strain [10], and very young age (infants) [11–16].
Despite the accumulating research on the development of 
complications associated with these risk factors, the increased 
risk and frequency of complications has not been systemati-
cally assessed. The objectives of the study were to estimate the 
overall prevalence of complications in hospitalized patients 
with culture-confirmed typhoid fever and to assess the effect of 
delaying the initiation of appropriate antimicrobial therapy and 
age on the prevalence and risk of complications.
METHODS
Search Strategy and Selection Criteria
We searched the PubMed database using the terms “typhoid 
fever,” “enteric fever,” “Salmonella Typhi,” “complication,” and 
“complications.” Results were restricted to publications in 
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English, listed from 1 January 1990 to 31 December 2018, where 
abstracts were available for review and research was conducted 
in human subjects. Publications with confirmed typhoid fever 
cases by blood, bone marrow, and/or stool culture and with 
disaggregated data on typhoid fever complications were selected 
for full review. Letters, reviews, editorials, case reports, case se-
ries reporting only one type of complications or one system 
affected, and studies not relevant to the subject of research, 
as well as publications where complication for nontyphoidal 
Salmonella or paratyphoid could not be disaggregated from ty-
phoid fever complications and studies reporting complications 
exported to developed countries, were excluded. The selection 
criteria and search terms for the study are listed in Table 1.
Two independent researchers screened the title and abstract 
of resulting articles based on the criteria described above. 
Discrepancies were resolved by reviewing the full article and 
confirming the selection criteria. Articles considered as rel-
evant for full review were downloaded and reviewed by one 
researcher. References were also screened to identify potential 
relevant articles not appearing in the initial search. Details of 
the search strategy are presented in Figure 1. No written pro-
tocol was published for this review.
Risk of Bias of Individual Studies
A set of criteria was developed to assess the risk of bias (RoB) of 
each relevant article and ensure that methods were sufficiently 
similar across articles to perform the meta-analysis [17, 18]. The 
three types of bias assessed were selection bias, detection bias, 
and reporting bias. For selection bias, we assessed how the cases 
were identified (laboratory-confirmed versus clinical diagnosis); 
whether or not the authors established clear exclusion criteria 
for cases with confounding illnesses such as immunodeficiency, 
malignancy, major congenital abnormalities or syndromes, 
and chronic illnesses; and whether the exclusion criteria were 
based on prior report of antimicrobial therapy, presentation 
of complications at recruitment, or antimicrobial resistance 
(AMR) patterns. For detection bias, we assessed the potential 
for misclassification via unclear definitions of complications 
and inclusion of a reduced group of all cases identified for sta-
tistical analyses. For reporting bias, we assessed the complete-
ness of reporting of complications of interest: whether all or a 
reduced group of complications observed were reported or not 
and whether key risk factors related to complications (days of 
disease before admission to the hospital and analysis of AMR) 
were reported. Based on these criteria, each article was classi-
fied as having low, medium, or high RoB (Table 2).
Data Extraction
Information on the overall occurrence of typhoid fever 
complications, days of disease at admission, antimicrobials 
used to assess resistance, and mortality reported in the arti-
cles included in the RoB analysis (n = 21) were extracted into 
an Excel spreadsheet (Microsoft, Redmond, Washington) and 
summarized in Table 3. Additionally, information on study 
objective, target population, recruitment, inclusion/exclusion 
criteria, definition of complications, and type of complications 
reported in each of these publications is presented in the 
Supplementary Material.
Data Analysis
The main objective of this meta-analysis was to estimate a 
pooled prevalence of typhoid fever complications and, second-
arily, to evaluate the effect of delaying appropriate antimicrobial 
therapy and age on the prevalence and risk of complications. 
The number of typhoid fever cases reported with complications 
and all culture-confirmed (blood, bone marrow, and/or stool 
culture) typhoid fever cases reported by each author were used 
in the meta-analysis. Any unfavorable evolution of the disease 
reported as a complication in a patient with typhoid fever in 
the publications included for analysis was considered a com-
plication; as a consequence, the list of complications generated 
for this review is entirely driven by what each author reported. 
The different types of complications listed by each article are in-
cluded in the Supplementary Material. Prevalence for each type 
of complication reported was estimated using as a numerator 
the sum of the frequencies for the specific complication and as 
the denominator the sum of all typhoid fever cases reported by 
the studies that measure the specific complication.
Description of individual-level data on antimicrobial suscep-
tibility of the Salmonella Typhi isolates and timing from disease 
onset to initiation of therapy needed to evaluate whether a pa-
tient received appropriate antimicrobial therapy was not avail-
able in the literature reviewed. The average days from disease 
onset to hospitalization (DDA) reported by the studies included 
Table 1.   Search Terms, Search Limits, and Selection Criteria for Study 
Inclusion From the PubMed Database Review
Search Terms
•  ((typhoid fever) OR (enteric fever) OR (Salmonella Typhi)) AND 
(complications OR complication)
Search Limits
• Published in English in peer-reviewed journal from 1 January 1990  
to 31 December 2018
• Abstracts available for review
• Research conducted in human subjects
Selection Criteria
• Typhoid fever cases identified from prospective/retrospective,  
cross-sectional, or surveillance studies
• Typhoid fever cases confirmed by blood culture, bone marrow culture,  
or stool culture
• Listed complications identified from culture-confirmed  
typhoid fever cases
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in the meta-analysis was used as a surrogate to assess the effect 
of delaying appropriate antimicrobial therapy on the prevalence 
and risk of complications.
The literature describes that complications usually develop 
by the second to fourth week of illness among typhoid fever 
patients not receiving appropriate diagnosis and/or treat-
ment [8]. However, a specific cutoff point to assess the effect 
of DDA on complications was not identified in the literature 
review. With the objective to identify a specific cutoff point, a 
preliminary analysis with the available information from six rel-
evant (low or medium RoB studies reporting illness duration 
at hospitalization) articles was performed, focusing on the pe-
riod from 2–4 weeks of illness duration. The results displayed 
differences in the prevalence of complications between studies 
with patients reporting an average of ≥10 days of disease onset 
at hospitalization and studies with patients reporting <10 days. 
The same result was observed after adding other articles with 
high RoB to the preliminary analysis. As a consequence, the 
10-day cutoff point was applied to the subgroup analysis (Figure 
2). The application of meta-regression to assess the effect of 
DDA on complications was not possible due to the few number 
of articles identified for this secondary analysis.
The mean or median days of disease at admission reported 
in each study were used to stratify data in two DDA groups. 
Group 1 included studies reporting a mean or median duration 
of disease of <10  days (DDA  <10). Group  2 included studies 
reporting a mean or median duration of disease of ≥10  days 
(DDA ≥10). Studies not describing the mean or median days 
of disease at admission but reporting the proportion of cases 
arriving at the hospital within the first week of the disease were 
assigned to group 1 or 2 using the following criterion: Studies 
with ≥60% typhoid fever cases arriving during the second week 
or later of the disease were included in group 2; otherwise, 
studies were included in group 1.
Figure 1. Study selection flow diagram (1990–2018).
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The effect of age on the prevalence and risk of complications was 
assessed using the prevalence of complications reported for chil-
dren and adults in the studies. Most studies included in the age 
group analysis reported complications in two age groups: children 
and adults. The age limits used to define the age group in each of 
these studies were used. Organizing the complications in newly de-
fined age groups with a specific cutoff point between children and 
adults was not possible due to the different age limits used across 
studies; the upper age limit for children varied from 12 to 15 years, 
whereas the lower age limit for adults varied from 14 to 16 years.
Analyses were conducted in Stata software version 15.1 
(StataCorp, College Station, Texas). Funnel plot analysis, with 
the Egger test, was used to assess for publication bias. We 
evaluated statistical significance at P  <.05. Sensitivity analysis 
was done using studies with high RoB, not included in the 
meta-analysis. Additionally, odds ratios (ORs) and χ 2 tests were 
used to evaluate for differential risks of complications between 
the DDA and age groups.
The meta-analysis was performed using a random-effects 
model assuming there were differences between the studies that 
were not caused by random chance, for example, differences in 
populations and context in which the studies took place. The I2 
statistic was used to measure the extent to which studies agreed 
with each other (heterogeneity). The estimated prevalence of ty-
phoid fever complications and overlapping of their 95% confi-
dence intervals (CIs) were visually inspected using forest plots, 
and heterogeneity between studies was verified in the overall 
and in the subgroup analysis. An I2 <30% was considered as 
representing low or unimportant heterogeneity; an I2 between 
30% and 50% as moderate heterogeneity, and >50% as substan-
tial/high heterogeneity [36].
RESULTS
The initial search in PubMed retrieved 2,397 records. After 
limiting articles to those published in English, published in 
PubMed between 1 January 1990 and 31 December 2018, re-
porting studies conducted in humans, and where abstracts were 
available for review, 816 (34%) articles remained. Review of 
titles and abstracts narrowed down the list to 64 relevant studies 
(Figure 1). Sixteen studies met inclusion criteria after full text 
review, and five additional records were added by supplemental 
review of reference lists.
Twenty-one studies were assessed for RoB for the meta-
analysis (Table 2). Five studies reported a list of typhoid fever 
complications observed but did not describe the total number of 
typhoid fever cases in which these complications were observed 
[29, 31–33, 35]. We did not assume that the total number of 
complications reported were equal to the total number of cases 
with complications as multiple complications can occur in a 
single patient. These studies were considered high RoB and 
were excluded from the meta-analysis. Three additional studies 
were excluded from the meta-analyses due to their selection 
criteria: one study excluded all typhoid fever cases found with 
complications at recruitment and/or infected with Salmonella 
Typhi strains fully susceptible to the antimicrobials tested by the 
authors [30]; the second study excluded patients with typhoid 
fever who received quinolones or cephalosporin or macrolides 
or chloramphenicol prior to enrollment [16]; and the third study 
excluded 26% of typhoid fever culture-confirmed cases due to in-
complete medical files, reducing the total number of typhoid fever 
cases included in the analysis [27]. We believed that these study 
characteristics created a unique and different group of typhoid 
fever cases that could not be compared with the rest of the studies, 
which included typhoid fever cases independent of resistance, 
development of complications, or pretreatment. These studies 
were, therefore, considered to have high RoB and were excluded 
from the meta-analysis. Finally, 13 studies, with low or medium 
RoB, were included in the meta-analysis [9, 10, 12, 19–26, 28, 34]. 
Information extracted from the 21 publications included in the 
RoB analysis is presented in Table 3 and Supplementary Material.
The 13 studies selected for the meta-analysis originated from 
seven countries in Asia (Thailand, Vietnam, Malaysia, Philippines, 
India, Indonesia, and China) and two countries in Africa (Malawi 
and South Africa). The studies included a total of 2,554 patients with 
typhoid fever, with 555 incurring complications. Five studies in-
cluded only children [10, 12, 20, 21, 34], two included only adults 
[9, 24], and six included individuals from all ages [19, 22, 23, 25, 26, 
28], with two of them reporting complication by age groups [19, 26] 
(Table 3). Thirteen studies were used to calculate the overall pooled 
prevalence of typhoid fever complications, nine to perform sub-
group analysis by age group (seven for children, four for adults), and 
six to perform subgroup analyses by DDA groups (four studies with 
DDA <10, two studies with DDA ≥10). Four of the seven studies 
reporting complications in children provided information for du-
ration of illness at hospitalization. These four studies were used to 
stratify the analysis by duration of illness (DDA groups) and explore 
differences in risk. Due to the limited number of publications, no 
analysis could be performed by AMR.
Further stratified analysis of DDA by region was not 
performed due to the small number of studies that provided 
this information (n  =  6). Four of the six studies included in 
the subgroup analysis by DDA originated from East Asia and 
Asia Pacific and two from South Asia (Figure 2A); none of the 
studies from Africa provided information on symptom dura-
tion. Within Asia, the two studies from South Asia reported the 
highest prevalence of complications for both DDA groups.
Overall Prevalence of Typhoid Fever Complications
Pooled analysis from the 13 studies resulted in an estimated 27% 
(95% CI, 21%–32%) of all blood culture–confirmed typhoid 
fever cases resulting in complications. A very high heterogeneity 
(I2 = 90.9%, P = .000) was found, indicating that the occurrence 
of typhoid fever complications reported was not consistent across 
the different studies (Figure 2A).
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The heterogeneity was reduced when studies were grouped 
by DDA, presenting fairly consistent estimates of the occur-
rence of typhoid fever complications within each group, despite 
variations in multidrug resistance and age (Figure 2A). The 
pooled prevalence of typhoid fever complications in studies re-
porting DDA ≥10 was higher (36% [95% CI, 29%–43%]) than 
Figure 2. Forest plots showing the overall and subgroup prevalence of typhoid fever complications among hospitalized patients (1990–2018), by illness duration at hos-
pitalization (A) and age (B). Abbreviations: A adults; All, all ages; C, children; CI, confidence interval; Comp, complications; DDA, mean/median illness duration (days) at 
hospitalization; ES, estimated prevalence; ID, study ID, study identification-first author (year of publication); MDR, multidrug antimicrobial resistance reported in each study; 
NR, not reported.
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the pooled prevalence from studies reporting DDA < 10 (16% 
[95% CI, 13%–18%]). Additionally, the odds of developing 
complications were three times greater in studies reporting 
DDA ≥10 compared with those seeking care earlier (OR, 3.00 
[95% CI, 2.14–4.17]; P < .0001).
The analysis by age group showed a higher pooled prevalence 
of typhoid fever complications from studies including children 
(27% [95% CI, 19%–35%]) than from studies including adults 
(17% [95% CI, 9%–25%]), with a very high heterogeneity for 
both groups (Figure 2B). The increased odds of developing 
complications observed in children was not significant (OR, 1.15 
[95% CI, .89–1.49]; P = .247). A subgroup analysis by DDA in 
the group of studies with children showed a higher prevalence 
of complications in children reporting DDA ≥10 compared to 
those seeking care earlier (36% [95% CI, 29%–43%] vs 14% 
[95% CI, 11%–16%]), translating in three times greater odds of 
developing complications for children with prolonged disease 
at hospitalization than children with shorter disease duration 
(OR, 3.25 [95% CI, 2.42–5.10]; P < .000). A stratified analysis 
by DDA in the group of studies with adults was not possible as 
only two of the four studies reported a DDA <10 and the other 
two studies did not provide information on illness duration at 
hospitalization.
The Egger test for the prevalence analysis was not sugges-
tive of the presence of publication bias (P = .259 for Figure 2A 
and P = .287 for Figure 2B).The sensitivity analyses conducted 
with two additional high RoB publications [16, 27], one of 
them with information on days of disease before hospitalization 
[16], resulted in similar pooled prevalences of typhoid fever 
complications (overall prevalence,  29% [95% CI, 23%–34%]; 
DDA <10, 16% [95% CI, 13%–18%]; DDA ≥10, 39% [95% CI, 
31%–47%]).
Occurrence of Specific Complications
The overall prevalence of each type of typhoid fever compli-
cation reported by the studies included in the meta-analysis, 
estimated using a random-effects model, is presented in Table 
4. Overall, the complications with the highest prevalence (95% 
CI) reported by at least three studies are encephalopathy, gas-
trointestinal bleeding, and nephritis, with a prevalence of 7.3% 
(2.8%–11.9%), 5.7% (2.4%–9.0%), and 4.8% (0.1%–9.4%), re-
spectively. When stratified by DDA group, the prevalence of 
complications reported in both groups differed (Figure 3). 
Hepatitis (5.1%) and gastrointestinal bleeding (4.0%) were the 
two most frequent complications reported in studies included 
in the DDA<10 group, whereas encephalopathy (18%) and 
gastrointestinal bleeding (14%) were the two most frequent 
complications in the studies from the DDA ≥10 group. Results 
from comparing the prevalence of complications reported in 
both groups (Table 5) revealed a higher risk for complications 
with DDA ≥10, with significant results for encephalopathy 
(OR, 6.81 [95% CI, 3.24–14.13]), cholecystitis (OR, 5.17 [95% 
CI, 1.29–24.32]), gastrointestinal bleeding (OR, 2.98 [95% CI, 
1.46–5.70]), and hepatitis (OR, 2.36 [95% CI, 1.29–4.27]).
DISCUSSION
Occurrence of Typhoid Fever Complications
Few publications met the criteria required for inclusion in this 
meta-analysis, highlighting the limited high-quality evidence 
available on typhoid fever complications in the published lit-
erature. Overall, the pooled results showed a higher prevalence 
(27% [95% CI, 21%–32%]) of typhoid fever complications 
among hospitalized patients than previously reported (10%–
15%) [1]. The stratified analyses revealed a higher prevalence 
of complications among patients reporting a mean/median of 
≥10 days of disease (36% versus 16%), with three times the risk 
for developing complications compared to patients reporting a 
mean/median of <10 days of disease onset at hospital admission. 
This higher prevalence and risk was also observed among spe-
cific complications such as hepatitis, gastrointestinal bleeding, 
encephalopathy, and cholecystitis.
Consistent with the literature reporting young age as a risk 
factor for disease severity [11–16], the analysis by age group 
showed a higher prevalence of complications from studies in-
cluding children than from studies including adults (27% versus 
17%, respectively). Nevertheless, the increased risk observed in 
children was not statistically significant. The stratified analysis 
by illness duration (DDA groups) showed a three times higher 
odds for developing complications among children with a DDA 
≥10 than among children with a DDA <10. This higher risk 
identified in children is similar to the risk identified in the anal-
ysis by DDA groups performed without taking into account age 
groups. These results suggest that, among children, there is also 
an increased risk of developing complications with a prolonged 
disease duration before hospitalization. However, it is important 
to highlight that across all studies included in the analysis, with 
and without data on illness duration, the highest prevalence of 
complications are reported in children, especially infants. We 
consider that incorrect diagnosis prior to hospitalization or de-
laying seeking care may lead to this disparity in complications 
at presentation to the hospital, as might the use of empirical 
antimicrobial agents to which the infecting Salmonella Typhi 
strain is resistant.
Assessment of the impact of AMR on the prevalence of ty-
phoid fever complications was not performed in this study. In 
the literature, however, patients infected with an antimicrobial-
resistant Salmonella Typhi strain experience more complications 
and greater disease severity in most studies [10, 12, 16, 22, 24, 
33, 35]. A  common factor that stands out in these studies, 
when reported, is the long duration of illness (mean/median 
of ≥10  days) before hospitalization [10, 16, 22, 33, 35]. This 
common factor is consistent with the results of the meta-
analysis, leading us to postulate that AMR could increase the 
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Table 4. Frequency and Prevalencea of Specific Typhoid Fever Complications Reported From Articles Included in the Meta-analysis (1990–2018)
Complication Frequency, No.
Total Group of Typhoid Fever Cases 
From Which Complications Are Re-
ported, No.
Prevalenceb, % 
(95% CI)
Study Reporting the Complication,  
First Author [Reference]
Aminotransferase elevation 28 88 32 (22–42) Song [25]
Acute kidney injury 2 470 0.3 (–.2 to .8) Malik [20], Limpitikul [21]
Anemia 41 693 5.8 (4–7.8) Limpitikul [21], Feasey [26]
Ascites 7 368 1.9 (.5–3.3) Limpitikul [21]
Blood transfusion 3 581 0.5 (–.1 to 1.1) Parry [19]
Bone marrow suppression 8 102 7.8 (2.6–13.1) Malik [20]
Bleeding or perforation 3 105 2.9 (–.3 to 6) van den Bergh [9]
Confusion 5 325 1.5 (.2–2.9) Feasey [26]
Changes in sensorium 3 60 5.0 (–.5 to 10.5) Kadhiravan [22]
Cholecystitis 18 854 3.2 (.2–6.1) Malik [20], Kabra [10], Rajajee [12], Parry 
[19]
Cyanotic episodes 3 71 4.2 (–.5 to 8.9) Rajajee [12]
Decreased consciousness 
level
13 325 4.0 (1.9–6.1) Feasey [26]
Encephalopathy 47 879 7.3 (2.8–11.9) Kabra [10], Parry [19], Kadhiravan [22], 
Mishra [34] Song [25]
Gastrointestinal bleeding 75 1251 5.7 (2.4–9.0) Kabra [10], Parry [19], Kadhiravan [22], 
Abucejo [23], Song [25]
Hemorrhage 4 180 2.2 (.1–4.4) Khosla [24]
Hemolysis 1 102 1.0 (–.9 to 2.9) Malik [20]
Hemodynamic shock 5 581 0.9 (.1–1.6) Parry [19]
Hemolytic anemia 3 368 0.8 (–.1 to 1.7) Limpitikul [21]
Hepatitis 71 1500 4.9 (2.3–7.5) Malik [20], Kabra [10], Parry [19], Khosla 
[24], Kadhiravan [22], Feasey [26], 
Mishra [34], Khan [28]
Hypothermia 10 71 14.1 (6.0–22.2) Rajajee [12]
Ileitis 21 422 5.0 (2.9–7.1) Abucejo [23]
Intestinal perforation 32 2268 1.1 (.4–1.8) Malik [20], Limpitikul [21], Kabra [10], Parry 
[19], Khosla [24], Abucejo [23], Feasey 
[26], Khan [28], Song [25]
Lower respiratory 
symptoms
7 368 1.9 (.5–3.3) Limpitikul [21]
Liver abscess 1 71 1.4 (–1.3 to 4.1) Rajajee [12]
Marrow hypoplasia 6 71 8.5 (2.0–14.9) Rajajee [12]
Meningitis 4 131 2.5 (–.2 to 5.2) Rajajee [12], Kadhiravan [22]
Myocarditis 41 1491 2.8 (1.5–4.0) Malik [20], Parry [19], Khosla [24], 
Kadhiravan [22], van den Bergh [9], 
Feasey [26], Mishra [34], Song [25]
Neuropsychiatric 
complications
24 180 13.3 (8.4–18.3) Khosla [24]
Nephritis/glomerulonephritis 16 273 4.8 (.1–9.4) Kabra [10], Rajajee [12], Khan [28]
Osteomyelitis 2 102 2.0 (–.7 to 4.7) Malik [20]
Paralytic ileus 12 282 4.2 (.4–8.1) Malik [20], Khosla [24]
Peripheral circulatory failure 2 180 1.1 (–.4 to 2.6) Khosla [24]
Peritonitis 2 88 2.3 (–.8 to 5.4) Song [25]
Pleural effusion 7 631 1.1 (.3–1.9) Parry [19], Mishra [34]
Pneumonia/bronchopneu-
monia
32 1234 2.5 (.7–4.2) Malik [20], Parry [19], Rajajee [12], van den 
Bergh [9], Feasey [26], Mishra [34]
Psychosis 20 524 3.8 (2.2–5.5) Malik [20], Abucejo [23]
Renal impairment 4 581 0.7 (.0–1.4) Parry [19]
SIADH 2 102 2.0 (–.7 to 4.7) Malik [20]
Seizure 1 368 0.3 (–.3 to .8) Limpitikul [21]
Sepsis syndrome 10 105 9.5 (3.9–15.1) van den Bergh [9]
Severe anemia 6 581 1.0 (.2–1.9) Parry [19]
Stupor or coma 3 105 2.9 (–.3 to 6.0) van den Bergh [9]
Transient thrombocytopenia 4 100 4.0 (.2–7.8) Kabra [10]
Abbreviations: CI, confidence interval; SIADH, syndrome of inappropriate antidiuretic hormone.
aIncludes data from publications that measured the specific complication. 
bPrevalence estimated using a random-effects model.
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occurrence of complications by allowing the disease to progress 
at least to ≥10 days before proper diagnosis and effective treat-
ment are implemented.
Whether the increased prevalence of complications observed 
among typhoid fever patients with ≥10  days of disease is 
due to the use of empirical antimicrobial agents to which 
the infecting organism is resistant needs further research. 
Overall, antimicrobial use prior to hospitalization was poorly 
documented among the articles reviewed and could not be 
evaluated here. Future research should disentangle the effects of 
delayed diagnosis from incorrect/ineffective first-line treatment 
and the effect of age on the development of complications. This 
would require consistent reporting of empirical antimicrobial 
use prior to hospitalization, days of disease at hospital ad-
mission, antimicrobial-resistant patterns, and presentation of 
complications in >2 age-stratified groups, information not re-
ported in most studies at present.
Mortality
Although not the focus of this meta-analysis, mortality was 
reported in eight of the 13 included studies. The mortality 
among the typhoid fever patients was low despite the high oc-
currence of complications described in some studies. Among 
the publications reporting deaths, fatal outcomes occurred 
among patients of all ages, with a mortality ranging from 0.5% 
(3/581) [19] to 6.7% (12/180) [24]. This mortality is similar to 
the median  (range) case fatality rate reported from hospital-
based studies by Crump et al in 2007 (2.0% [0–14.8%]) [4]. It 
is important to highlight that all patients included in this meta-
analysis were followed up and received appropriate treatment 
in a hospital setting, two critical factors that likely contributed 
to the low mortality observed among the complicated typhoid 
fever cases.
Limitations
The few number of articles included in the meta-analysis 
for the estimation of the overall and subgroup prevalence of 
complications is one of the main limitations to the results of this 
study. Only Thirteen of the relevant articles (Table 2) identified 
with the systematic review were included in the meta-analysis 
due to differences in the methods to select typhoid fever cases, 
measure complications, and report complications. The low 
number of studies included in the analysis also limits the inves-
tigation of reporting bias.
In addition to the scarcity of quality data, not all studies 
consistently report prior empirical antimicrobial use; days of 
disease at hospital admission; AMR patterns; the definitions 
used to measure complications, which is a critical factor that 
Figure 3. Frequency (pooled across the studies reporting the complications and 
illness duration  at hospitalization) of typhoid fever complications (1990–2018). 
Abbreviation: DDA, mean/median illness duration at hospitalization.
Table 5. Risk Analysesa of Typhoid Fever Complications Among Hospitalized Patients Reporting Illness Duration at Hospitalization (1990–2018)
Complication
DDA ≥10 DDA <10
OR (95% CI) P-Value
Frequency, 
No.
Typhoid 
fever 
Cases, 
No. Prevalenceb, % [Reference]
Frequency, 
No.
Typhoid 
fever 
Cases, 
No. Prevalenceb, % [Reference]
Acute kidney 
injury
1 102 1.0 [20] 1 368 0.3 [21] 3.63 (.04–285.97) .330
Cholecystitis 7 202 3.4 [10, 20] 4 581 0.7 [19] 5.17 (1.29–24.32) .003
Encephalo-
pathy
18 100 18.0 [10] 20 641 3.4 [19, 22, 23] 6.81 (3.24–14.13) .000
GI bleeding 14 100 14.0 [10] 55 1063 4.0 [19, 22, 23] 2.98 (1.46–5.70) .000
Hepatitis 23 202 10.9 [10, 20] 33 641 5.1 [19, 22] 2.36 (1.29–4.27) .001
Intestinal  
perforation
3 202 1.5 [10, 20] 8 1371 0.4 [19, 21, 23] 2.56 (.43–10.80) .151
Myocarditis 4 102 3.9 [20] 13 641 2.0 [19, 22] 1.97 (.45–6.54) .234
Pneumonia 1 102 1.0 [20] 5 581 0.9 [19] 1.14 (.02–10.34) .904
Psychosis 4 102 3.9 [20] 16 422 3.8 [23] 1.03 (.24–3.30) .950
Abbreviations: CI, confidence interval; DDA, mean/median illness duration at hospitalization; GI, gastrointestinal; OR, odds ratio.
aIncludes data from publications that measured the specific complication. 
bPrevalence estimated using a random-effects model.
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influences the prevalence of complications reported; and the 
occurrence of complications stratified by age group.
Additionally, the capacity to diagnose some complications, 
such as availability of ultrasound, electrocardiography, and lab-
oratory tests to diagnose cholecystitis, myocarditis, hepatitis, 
and so on, may vary substantially between sites and influence 
reported complication rates. From the 21 relevant articles, only 
one study described the criteria used to measure and identify 
each of the complications observed and reported [19]; twelve 
studies reported days of disease or fever at hospitalization 
[10, 16, 19–23, 28, 30, 31, 33, 35]; four studies lacked the re-
port of antimicrobial analysis [9, 26, 28, 31]; three studies re-
ported prior antimicrobial use [20, 22, 23]; three of the seven 
studies including cases from all ages reported the occurrence of 
complications categorized by at least two age groups [16, 19, 26]; 
and five reported complications but not the number of patients 
with complications [29, 31–33, 35]. These data gaps limited the 
assessment of the impact of risk factors on complications.
We further highlight the limited publications on typhoid 
fever complications from Africa and South America and the 
variability of antimicrobials used to assess resistance. While 
multidrug resistance was reported in 15 of the 21 articles 
reviewed, susceptibility to nalidixic acid was assessed in only 
five studies [16, 19, 22, 25, 30]. Resistance to nalidixic acid 
or intermediate resistance to fluoroquinolones, rather than 
multidrug resistance, has been associated with typhoid fever 
severity and complications [16, 19]. Future studies should 
test for decreased susceptibility, or intermediate resistance, to 
fluoroquinolones in Salmonella Typhi, by testing for nalidixic 
acid or pefloxacin resistance or by ciprofloxacin minimum in-
hibitory concentrations, and report complications stratified 
by antimicrobial susceptibility pattern of infecting isolates. 
Furthermore, the pathogenic potential of the strain genotype 
could also affect the severity of typhoid fever [19]; however, that 
information is not routinely collected or reported.
Another limitation is the setting in which these studies 
took place. All studies were hospital-based and, as such, the 
criteria for hospital admission is likely to vary across studies 
and there is an increased risk of overestimating the occur-
rence of complications by measuring complications in typhoid 
fever patients with severe disease and access to healthcare [37]. 
Furthermore, limiting the report of complications to patients 
with culture-positive cases may result in bias toward more severe 
cases. Differences in geographical regions could not be assessed 
due to the limited number of published articles identified with 
enough quality to be included in the meta-analysis.
Last, the subgroup analysis by DDA and age group is based 
on aggregated rather than individualized data, which enabled 
comparisons across studies but not within studies. As a surrogate 
for delaying the implementation of effective antimicrobial treat-
ment, we utilized mean/median DDA to dichotomize studies 
for comparison, using a threshold of 10 days; however, it is pos-
sible that most complications occur among individuals with 
much longer DDA and that our comparison underestimated the 
effects of disease duration on complications. A meta-regression 
could not be performed due to the few number of eligible articles 
(with low or medium RoB and reporting DDA data) included 
for this analysis (n = 6). For the age group analysis, we used the 
groups (children and/or adults) reported by the studies and not 
a standard cutoff point due to limited age-stratified information 
for complications that would allow us to organize cases in de-
fined age groups. This approach may have underestimated the 
effect of age on the prevalence and risk of complications, espe-
cially in very young children. Lack of data on duration of illness 
also limited the stratification of adults by this variable.
CONCLUSIONS
This systematic literature review found limited quality evidence 
concerning culture positive typhoid fever complications in 
the published literature. The meta-analysis identified a higher 
overall prevalence of complications than previously reported 
with a higher risk of typhoid fever complications for patients, 
including children, with a prolonged duration of disease prior 
to hospitalization, possibly driven by a delay in hospitalization 
and the administration of effective antimicrobial treatment. 
Typhoid fever cases from studies reporting a mean/median of 
≥10 days of symptom duration at hospitalization not only have 
a higher prevalence of complications (36% versus 16%), but also 
three times the risk for developing complications compared 
with typhoid fever patients from studies reporting a mean/me-
dian of <10  days of symptoms at hospitalization. This higher 
risk was also observed from studies including children and 
reporting duration of illness at hospitalization. However, the 
results of this study should be interpreted with caution because 
of the limited number of publications included, as many articles 
were excluded for high RoB.
These results underscore the importance of adequate health 
infrastructure with early access to diagnosis and adequate treat-
ment among patients with typhoid fever to reduce complications 
and severity of the disease. In high-risk countries with high 
AMR prevalence and limited access to healthcare, prevention 
and control strategies should be comprehensive and include re-
duction of barriers to healthcare access, improved diagnostics, 
and increased availability of new vaccines recommended by the 
World Health Organization [38].
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